Rybelsus, a groundbreaking treatment for type 2 diabetes, represents a new class of medication known as GLP-1 receptor agonists. Unlike traditional injectables, Rybelsus offers patients an oral option, dramatically improving the convenience of diabetes management. Its active ingredient, semaglutide, mimics the body’s natural incretin hormones, which play a pivotal role…